Dáil Éireann Debate, Thursday - 14 December 2023
520. Deputy Bernard J. Durkan asked the Minister for Health the reason a person (details supplied) has been advised to seek possible treatment for his condition abroad given that he has lived in this country and has been employed here, and whose home is in this country for many years, who is a patient of Tallaght hospital; and if he will make a statement on the matter. [56276/23]
View answerThe Health Act 1970 (as amended) provides for two categories of eligibility for persons ordinarily resident in the country, i.e. full eligibility (medical card holders) and limited eligibility (all others). Adults with full eligibility can access a range of services including GP services, prescribed drugs and medicines, public in-patient hospital services, including consultants’ services, out-patient public hospital services including consultants’ services, dental, ophthalmic and aural services and appliances, and maternity and infant care service. Persons with limited eligibility are eligible for in-patient and outpatient public hospital services including Consultant services, Emergency Department or minor injury care, subject to certain charges. Other services such as allied healthcare professional services may also be made available to persons with limited eligibility.
In addition, patients have the option to access treatment abroad under two EU schemes operated by the HSE. The HSE operates the EU Treatment Abroad Scheme (TAS), for persons entitled under EU Regulation 883/04. The TAS is a consultant led scheme and allows for an Ireland-based public consultant to refer a public patient who is normally resident in Ireland for treatment in the public healthcare system of another EU member state, the UK or Switzerland. Subject to the EU Regulations and Guidelines, the TAS provides for the cost of approved public treatments in another EU/EEA member state, the UK or Switzerland through the issue of form S2 (IE) where the treatment is:
• among the benefits provided for by Irish legislation;
• not available in Ireland;
• not available within the time normally necessary for obtaining it in Ireland, taking account of the patient's current state of health and the probable course of the disease;
• medically necessary and will meet the patient’s needs;
• a proven form of medical treatment and not experimental or test treatment;
• provided in a recognised public hospital or other institution that will accept EU/EEA form S2 (IE) and;
• is under the control of a registered medical practitioner.
The HSE provides further information for patients on the HSE TAS website: www2.hse.ie/services/schemes-allowances/treatment-abroad-scheme/
The EU Cross Border Directive (CBD) provides rules for the reimbursements to patients of the cost of receiving treatment abroad, where the patient would be entitled to such treatment in their home Member State, and supplements the rights that patients already have at EU level. The HSE operates the EU Cross Border Directive (CBD) in Ireland. Under the terms of the CBD, patients in Ireland can seek to be referred to another EU/EEA country for medical treatment that is available in the public health service in Ireland. The patient may access the overseas service in either the public or private health sector of the country they choose to receive the service in. The patient pays for the treatment and claims reimbursement from the HSE at the cost of that treatment in Ireland or the cost of it abroad, whichever is the lesser. The HSE, in fulfilling its role as the National Contact Point (NCP) in Ireland, provides information for patients on the operation of the CBD, including on its website: www2.hse.ie/services/schemes-allowances/cross-border-directive/
